Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Cancer Letters

Volumn 350, Issue 1-2, 2014, Pages 25-33

  Sudha, Thangirala ^a   Yalcin, Murat ^a,b   Lin, Hung Yun ^c   Elmetwally, Ahmed M ^a   Nazeer, Tipu ^d   Arumugam, Thiruvengadam ^e   Phillips, Patricia ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d ALBANY MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti cancer; Low molecular weight heparin; Non anticoagulant heparin; Pancreatic cancer; Tumor suppressor; Tumor survival

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; SULFATED NON ANTICOAGULANT HEPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SULFATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUMINESCENCE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR NECROSIS;

ANTI-CANCER; LOW MOLECULAR WEIGHT HEPARIN; NON-ANTICOAGULANT HEPARIN; PANCREATIC CANCER; TUMOR SUPPRESSOR; TUMOR SURVIVAL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DEOXYCYTIDINE; ENZYME INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901494319     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.016     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007, CA. Cancer J. Clin. 2007, 57(2007):43-66.
2. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
3. Sgouros J., Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncol. 2008, 47:337-346.
4. Fareed J., Leong W.L., Hoppensteadt D.A., Jeske W.P., Walenga J., Wahi R., Bick R.L. Generic low-molecular-weight heparins: some practical considerations. Semin. Thromb. Hemost. 2004, 30:703-713.
5. Oguchi T., Doursout M.F., Kashimoto S., Liang Y.Y., Hartley C.J., Chelly J.E. Role of heparin and nitric oxide in the cardiac and regional hemodynamic properties of protamine in conscious chronically instrumented dogs. Anesthesiology 2001, 94:1016-1025.
6. Salas A., Sans M., Soriano A., Reverter J.C., Anderson D.C., Pique J.M., Panes J. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000, 47:88-96.
7. Vlodavsky I., Ilan N., Nadir Y., Brenner B., Katz B.Z., Naggi A., Torri G., Casu B., Sasisekharan R. Heparanase, heparin and the coagulation system in cancer progression. Thromb. Res. 2007, 120(Suppl. 2):S112-120.
8. Ludwig R.J., Boehme B., Podda M., Henschler R., Jager E., Tandi C., Boehncke W.H., Zollner T.M., Kaufmann R., Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004, 64:2743-2750.
9. Icli F., Akbulut H., Utkan G., Yalcin B., Dincol D., Isikdogan A., Demirkazik A., Onur H., Cay F., Buyukcelik A. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol. 2007, 95:507-512.
10. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., Prins M.H., Raskob G., Segers A.E., Cariou R., Leeuwenkamp O., Lensing A.W. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. 2004, 140:867-873.
11. Pross M., Lippert H., Misselwitz F., Nestler G., Kruger S., Langer H., Halangk W., Schulz H.U. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb. Res. 2003, 110:215-220.
12. Mousa S.A., Petersen L.J. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb. Haemost. 2009, 102:258-267.
13. Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecular-weight heparin. Thromb. Haemost. 2008, 99:807-818.
14. von Delius S., Ayvaz M., Wagenpfeil S., Eckel F., Schmid R.M., Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb. Haemost. 2007, 98:434-439.
15. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst. 1999, 91:22-36.
16. Akl E.A., van Doormaal F.F., Barba M., Kamath G., Kim S.Y., Kuipers S., Middeldorp S., Yosuico V., Dickinson H.O., Schunemann H.J. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst. Rev. 2007, CD006652.
17. Iorio A., Guercini F., Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J. Thromb. Haemost. 2003, 1:1906-1913.
18. Mousa S.A. Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc) 2006, 42:331-350.
19. Cox M., Nelson D. Lehninger, Principles of Biochemistry 2004, Freeman, WH.
20. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., Kakkar A.K., Prins M., Levine M.N. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 2005, 23:2123-2129.
21. Vlodavsky I., Abboud-Jarrous G., Elkin M., Naggi A., Casu B., Sasisekharan R., Ilan N. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol. Haemost. Thromb. 2006, 35:116-127.
22. Mousa S.A., Linhardt R., Francis J.L., Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 2006, 96:816-821.
23. Mousa S.A. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Int. Angiol. 2006, 25:10-13.
24. Yalcin M., Bharali D.J., Lansing L., Dyskin E., Mousa S.S., Hercbergs A., Davis F.B., Davis P.J., Mousa S.A. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009, 29:3825-3831.
25. Davis P.J., Shih A., Lin H.Y., Martino L.J., Davis F.B. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J. Biol. Chem. 2000, 275:38032-38039.
26. Zhang S., Cao H.J., Davis F.B., Tang H.Y., Davis P.J., Lin H.Y. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br. J. Cancer 2004, 91:178-185.
27. Tsuzuki Y., Mouta Carreira C., Bockhorn M., Xu L., Jain R.K., Fukumura D. Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab. Invest. 2001, 81:1439-1451.
28. Ramachandran V., Arumugam T., Hwang R.F., Greenson J.K., Simeone D.M., Logsdon C.D. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res. 2007, 67:2666-2675.
29. Caceres G., Zhu X.Y., Jiao J.A., Zankina R., Aller A., Andreotti P. Imaging of luciferase and GFP-transfected human tumours in nude mice. Luminescence 2003, 18:218-223.
30. Casu B., Vlodavsky I., Sanderson R.D. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Thromb. 2008, 36:195-203.
31. Mousa S.A., Feng X., Xie J., Du Y., Hua Y., He H., O'Connor L., Linhardt R.J. Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms. J. Cardiovasc. Pharmacol. 2006, 48:6-13.
32. Amirkhosravi A., Meyer T., Amaya M., Davila M., Mousa S.A., Robson T., Francis J.L. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin. Thromb. Hemost. 2007, 33:643-652.
33. Riess H., Pelzer U., Hilbig A., Stieler J., Opitz B., Scholten T., Kauschat-Bruning D., Bramlage P., Dorken B., Oettle H. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008, 8:361.
34. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., Prandoni P., Bos M.M., Richel D.J., van Tienhoven G., Buller H.R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005, 23:2130-2135.
35. Phillips P.G., Yalcin M., Cui H., Abdel-Nabi H., Sajjad M., Bernacki R., Veith J., Mousa S.A. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011, 31:411-419.
36. Stevenson J.L., Varki A., Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb. Res. 2007, 120(Suppl. 2):S107-111.
37. Angelini A., Di Febbo C., Ciofani G., Di Nisio M., Baccante G., Di Ilio C., Cuccurullo F., Porreca E. Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol. Ther. 2005, 4:313-317.
38. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 2005, 14(Suppl. 1):35-48.